KEAP1 and familial pancreatic carcinoma: To conclude we can assert that esculetin is a good potential therapeutic agent for pancreatic cancer, where it activates the Nrf2-ARE pathway by binding to KEAP1 protein and ultimately suppresses cancer cell population growth through ROS sensitive transcription factor NFκB.